NOR-SWITCH was a randomised, double-blind, non-inferiority parallel-group study that compared the effect of switching from Remicade®† to Inflectra/CT-P13* (infliximab) in 481 patients across all indications.§1
There was a similar adverse event profile in stable patients switching from Remicade®† to CT-P13*, compared with those remaining on Remicade®.§
Safety population. Data are number of events/number of patients (%).
Created from Jørgensen KK, et al. 2017.
Learn about the safety and clinical evidence supporting the use of Inflectra in patient with rheumatoid arthritis
Read the guidance on optimising treatment with Inflectra and TDM and biomarkers
Find out more
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020